Pulmonary Medicine at Shanghai Chest Hospital | CMCS

Expert Pulmonary Medicine at One of Shanghai's Premier Thoracic Specialty Centers

The Department of Pulmonary Medicine at Shanghai Chest Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is one of China's most distinguished pulmonary medicine centers, with a national reputation for excellence in lung cancer medical oncology, targeted therapy, immunotherapy, interventional pulmonology, respiratory critical care, and the management of complex pulmonary conditions. As a dedicated cardiothoracic specialty hospital, Shanghai Chest Hospital offers uniquely integrated pulmonary medicine and thoracic surgical expertise under one roof, enabling seamless multidisciplinary care for patients with lung cancer and complex pulmonary disease. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their pulmonary care journey.

About the Department

The pulmonary medicine department is a national key clinical specialty operating dedicated pulmonary medicine wards, a respiratory ICU (RICU), a bronchoscopy and interventional pulmonology suite, a pulmonary function laboratory, a sleep medicine center, a pulmonary rehabilitation program, and works in close collaboration with thoracic surgery, radiation oncology, pathology, and molecular diagnostics through a fully integrated multidisciplinary lung cancer team (MDT).

Lung Cancer — Medical Oncology & Targeted Therapy

Non-Small Cell Lung Cancer (NSCLC)

• EGFR-Mutant NSCLC — Osimertinib (FLAURA2 first-line); Amivantamab + Lazertinib (MARIPOSA); Osimertinib + chemotherapy (FLAURA2); EGFR exon 20 insertion: Amivantamab, Mobocertinib; T790M resistance: Osimertinib; C797S resistance: EGFR/MET bispecific strategies; one of Shanghai's most experienced EGFR-mutant NSCLC programs
• ALK-Rearranged NSCLC — Alectinib (ALEX); Brigatinib (ALTA-1L); Lorlatinib (CROWN — first-line); ALK resistance: Lorlatinib after 1st/2nd gen; compound mutations: next-generation sequencing guided; one of Shanghai's most experienced ALK+ NSCLC programs
• ROS1-Rearranged NSCLC — Crizotinib; Entrectinib; Repotrectinib (TRIDENT-1 — ROS1 TKI-naïve and pretreated); one of China's most experienced ROS1+ NSCLC programs
• KRAS G12C NSCLC — Sotorasib (CodeBreaK 200); Adagrasib (KRYSTAL-1); Adagrasib + Cetuximab; one of Shanghai's most experienced KRAS G12C NSCLC programs
• MET Exon 14 Skipping NSCLC — Tepotinib (VISION); Capmatinib (GEOMETRY mono-1); Savolitinib (China-approved); one of Shanghai's most experienced MET ex14 NSCLC programs
• RET-Rearranged NSCLC — Selpercatinib (LIBRETTO-001); Pralsetinib (ARROW); one of China's most experienced RET+ NSCLC programs
• NTRK-Fusion NSCLC — Larotrectinib; Entrectinib; Repotrectinib for TRK inhibitor-resistant disease
• HER2-Mutant NSCLC — Trastuzumab deruxtecan (T-DXd; DESTINY-Lung02); Pyrotinib (China-approved); one of Shanghai's most experienced HER2-mutant NSCLC programs
• BRAF V600E NSCLC — Dabrafenib + Trametinib; one of China's most experienced BRAF V600E NSCLC programs

Immunotherapy for NSCLC

• PD-L1 High (TPS ≥50%) — Pembrolizumab monotherapy (KEYNOTE-024); Cemiplimab (EMPOWER-Lung 1); Sintilimab (ORIENT-11); Tislelizumab (RATIONALE 303)
• Chemo-Immunotherapy — Pembrolizumab + chemotherapy (KEYNOTE-189/407); Atezolizumab + bevacizumab + chemotherapy (IMpower150); Sintilimab + chemotherapy (ORIENT-11/12); Camrelizumab + chemotherapy (CameL/CameL-sq)
• Dual Immunotherapy — Nivolumab + Ipilimumab (CheckMate 227/9LA); for TMB-high or PD-L1 positive NSCLC
• Perioperative Immunotherapy — Neoadjuvant Nivolumab + chemotherapy (CheckMate 816); Adjuvant Atezolizumab (IMpower010); Adjuvant Pembrolizumab (KEYNOTE-091); Neoadjuvant + adjuvant Pembrolizumab (KEYNOTE-671)

Small Cell Lung Cancer (SCLC)

• Extensive-Stage SCLC — Atezolizumab + carboplatin + etoposide (IMpower133); Durvalumab + chemotherapy (CASPIAN); Serplulimab + chemotherapy (ASTRUM-005 — China-approved)
• Relapsed SCLC — Topotecan; Lurbinectedin; Tarlatamab (DLL3-targeted BiTE; DeLLphi-301 — FDA-approved 2024); one of Shanghai's most experienced relapsed SCLC programs
• Limited-Stage SCLC — Concurrent chemoradiation; prophylactic cranial irradiation (PCI) coordination; Durvalumab consolidation (ADRIATIC)

Interventional Pulmonology

• Endobronchial Ultrasound (EBUS-TBNA) — Mediastinal and hilar lymph node staging; tissue diagnosis; rapid on-site evaluation (ROSE); one of Shanghai's most experienced EBUS programs
• Navigational Bronchoscopy — Electromagnetic navigation (superDimension); robotic bronchoscopy (Monarch, Ion); peripheral pulmonary lesion biopsy; one of China's most experienced navigational bronchoscopy programs
• Endobronchial Tumor Ablation — Argon plasma coagulation (APC); cryotherapy; electrocautery; laser; for central airway obstruction
• Airway Stenting — Silicone and self-expanding metallic stents; malignant and benign central airway obstruction; tracheal stenosis; one of Shanghai's most experienced airway stenting programs
• Rigid Bronchoscopy — For complex central airway obstruction; tumor debulking; foreign body removal; one of China's most experienced rigid bronchoscopy programs
• Medical Thoracoscopy — Pleural effusion diagnosis; pleural biopsy; talc pleurodesis; one of Shanghai's most experienced medical thoracoscopy programs
• Bronchial Thermoplasty — For severe refractory asthma; one of China's most experienced bronchial thermoplasty programs
• Endobronchial Valve (EBV) — Zephyr valve; for severe emphysema with intact interlobar fissures; one of China's most experienced EBV programs

Respiratory Medicine — Non-Oncologic Conditions

• Chronic Obstructive Pulmonary Disease (COPD) — Triple inhaled therapy (LAMA+LABA+ICS); Dupilumab for eosinophilic COPD (BOREAS/NOTUS); pulmonary rehabilitation; one of Shanghai's most experienced COPD programs
• Asthma — Severe asthma biologics: Mepolizumab (MENSA), Benralizumab (CALIMA/SIROCCO), Dupilumab (LIBERTY ASTHMA QUEST), Tezepelumab (NAVIGATOR); bronchial thermoplasty; one of Shanghai's most experienced severe asthma programs
• Interstitial Lung Disease (ILD) — IPF: Nintedanib (INPULSIS), Pirfenidone (CAPACITY/ASCEND); Systemic sclerosis-ILD: Nintedanib (SENSCIS); PF-ILD: Nintedanib (INBUILD); one of Shanghai's most experienced ILD programs
• Pulmonary Hypertension — ERA: Ambrisentan, Macitentan (SERAPHIN); PDE5i: Sildenafil, Tadalafil; Prostacyclin: Selexipag (GRIPHON); Sotatercept (STELLAR); one of Shanghai's most experienced PAH programs
• Pleural Disease — Malignant pleural effusion; pleural mesothelioma; empyema; pneumothorax; indwelling pleural catheter (IPC); one of Shanghai's most experienced pleural disease programs
• Sleep-Disordered Breathing — Polysomnography; CPAP/BiPAP titration; hypoglossal nerve stimulation (Inspire); one of Shanghai's most experienced sleep medicine programs
• Respiratory Failure & Critical Care — RICU; invasive and non-invasive mechanical ventilation; HFNC; ECMO coordination; one of Shanghai's most experienced respiratory critical care programs

Why International Patients Choose Shanghai Chest Hospital Pulmonary Medicine

• Lung Cancer Precision Medicine — Comprehensive NGS for all actionable mutations; access to all approved targeted therapies and immunotherapy agents; clinical trial access
• Integrated Thoracic MDT — Pulmonary medicine, thoracic surgery, radiation oncology, pathology, and molecular diagnostics under one roof; weekly lung cancer MDT
• Advanced Interventional Pulmonology — Robotic bronchoscopy; navigational bronchoscopy; EBUS; rigid bronchoscopy; airway stenting; one of China's most comprehensive interventional pulmonology programs
• Tarlatamab for Relapsed SCLC — One of Shanghai's most experienced centers for this novel DLL3-targeted BiTE for relapsed small cell lung cancer
• Cost-Effectiveness — World-class pulmonary oncology and interventional pulmonology at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your pulmonary diagnosis, CT/PET-CT scans, pathology reports, molecular testing results, and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate pulmonologist or thoracic oncologist based on your condition.
4. MDT Submission — We facilitate pre-arrival lung cancer MDT case review for complex cases.
5. Priority Scheduling — We secure a consultation slot with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near Shanghai Chest Hospital, and Shanghai airport transfers.
7. On-Site Coordination — Full coordination of bronchoscopy, molecular testing, treatment initiation, and inpatient admission if required.
8. Post-Treatment Follow-Up — Treatment report translation, imaging review coordination, and remote follow-up after you return home.

Book a Consultation

If you require lung cancer targeted therapy, immunotherapy, interventional pulmonology, or management of complex pulmonary conditions — CMCS can arrange a specialist consultation with Shanghai Chest Hospital's pulmonary medicine team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com